Industries > Pharma > Antisense and RNAi Therapeutics Market Report to 2031
Antisense and RNAi Therapeutics Market Report to 2031
By Technology (RNA Interference, Antisense RNA), By Application (Oncology, Cardiovascular Diseases (CVDS), Infectious Diseases, Genetic Disorders, Others), By Administration (Pulmonary Delivery, Intravenous Injections, Intra-Dermal Injections, Others). By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa)
Antisense and RNAi Therapeutics Market– our new study reveals trends, R&D progress, and predicted revenues
Where is the Antisense and RNAi Therapeutics market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our Antisense and RNAi Therapeutics report provides tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Antisense and RNAi Therapeutics Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), product profiles and commercial developments.
Antisense and RNAi Therapeutics Market by Technology
• RNA Interference
• Antisense RNA
Antisense and RNAi Therapeutics Market byApplication
• Oncology
• Cardiovascular Diseases (CVDs)
• Infectious Diseases
• Genetic Disorders.
• Others
Antisense and RNAi Therapeutics Market by Administration
• Pulmonary Delivery
• Intravenous Injections
• Intra-dermal Injections
• Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Japan
o Rest of Asia Pacific
• Latin America
o Rest of Latin America
• Middle East and Africa
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Antisense and RNAi Therapeutics Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Antisense and RNAi Therapeutics Market with forecasts for by technology, by application, by administration each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments
Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Antisense and RNAi Therapeutics Market report helps you
In summary, our 290+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Antisense and RNAi Therapeutics Market, with forecasts for by technology, by application, by administration, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 20 key national markets – See forecasts for the Antisense and RNAi Therapeutics market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, Rest of Asia Pacific, Latin America and Middle East and Africa among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for Antisense and RNAi Therapeutics of the major companies involved in the Antisense and RNAi Therapeutics Market. Some of the company’s profiled in this report include-
• Tekmira Pharmaceuticals
• Ionis Pharmaceuticals
• Glaxo Smith Kline
• Alnylam Pharmaceuticals Inc.
• Antisense Therapeutics
• Sanofi-Genzyme
• Silence Therapeutics
• F. Hoffmann-La Roche Ltd
• Sirnaomics Inc.
• Gene Signal
• BioNTech
• Quark Pharmaceuticals,
• CureVac AG
• Gradalis Inc
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
With Information found nowhere else- our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.
Visiongain’s study is for everybody needing commercial analyses for the global Antisense and RNAi Therapeutics Market and leading companies. You will find data, trends, and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Antisense and RNAi Therapeutics Market Report to 2031: By Technology (RNA Interference, Antisense RNA), By Application (Oncology, Cardiovascular Diseases (CVDS), Infectious Diseases, Genetic Disorders, Others), By Administration (Pulmonary Delivery, Intravenous Injections, Intra-Dermal Injections, Others). By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Antisense & RNAi Therapeutics Market
2.1. Antisense & RNAi Therapeutics Market Definition
2.2. By Technology Submarkets Definitions
2.3. By Application Submarkets Definitions
2.4. By Administration Submarkets Definitions
3. Antisense & RNAi Therapeutics Market Overview
3.1. Global Antisense & RNAi Therapeutics Market Size and Forecast by Region
3.2. Global Antisense & RNAi Therapeutics Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing collaborations among bio-pharmaceutical companies
3.3.1.2. Increasing pipeline product portfolio
3.3.1.3. Introduction of technological advancements.
3.3.1.4. Government initiatives & funding for R&D.
3.3.2. Market Restraints/Challenges
3.3.2.1. Expensive research programs
3.3.2.2. Delivery of RNAi therapeutics and off-target effects
3.3.3. Opportunities
3.3.3.1. Rising approval &drug launch of RNA therapeutics plays significant role in the growth of the market.
3.3.3.2. Increasing application in molecular diagnostics.
3.3.4. Porter’s Five Forces Analysis
3.3.4.1. Competitive Rivalry
3.3.4.2. Supplier Power
3.3.4.3. Buyer Power
3.3.4.4. Threat of Substitution
3.3.4.5. Threat of New Entry
4. Global Antisense & RNAi Therapeutics Market Analysis and Forecast 2021-2031, By Technology (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. RNA Interference
4.1.2. RNA interference (RNAi) biological response to double-stranded RNA, which intermediates resistance to endogenous parasitic and exogenous pathogenic nucleic acids.
4.1.3. Antisense RNA
4.1.4. Single stranded RNA, which is complementary to a protein coding messenger RNA (mRNA).
5. Global Antisense & RNAi Therapeutics Market Analysis and Forecast, 2021-2031 By Application (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Oncology
5.1.2. Antisense technology, siRNA, and therapeutic mRNA emerge as potential cancer therapeutics.
5.1.3. Cardiovascular Diseases (CVDs)
5.1.4. miRNAs therapeutics have significant potential in evolution of cardiovascular diseases, such as acute myocardial infarction (AMI), fibrosis, and heart failure.
5.1.5. Infectious Diseases
5.1.6. Antisense-based therapeutics have the potential to lead in anti-infective drug development.
5.1.7. Genetic Disorders.
5.1.8. Approval of RNA-targeted drugs for the treatment of rare genetic disease.
5.1.9. Others
6. Global Antisense & RNAi Therapeutics Market Analysis and Forecast, 2021-2031 By Administration (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Pulmonary Delivery
6.1.2. The pulmonary drug delivery have high drug-loading efficiency.
6.1.3. Intravenous Injections
6.1.4. Eliminates drug absorption and breakdown by directly depositing it into the blood.
6.1.5. Intra-dermal Injections
6.1.6. Oligonucleotides short fragments of nucleic acids administered into dermis.
6.1.7. Others
7. North America Antisense & RNAi Therapeutics Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. North America Antisense & RNAi Therapeutics Market Size and Forecast By Technology
7.3. North America Antisense & RNAi Therapeutics Market Size and Forecast By Application
7.4. North America Antisense & RNAi Therapeutics Market Size and Forecast By Administration
7.5. U.S. Antisense & RNAi Therapeutics Market
7.5.1. Emerging biopharmaceutical companies to develop RNA based therapeutics.
7.6. Canada Antisense & RNAi Therapeutics Market
7.6.1. Major players involved in developing RNA therapeutics.
8. Europe Antisense & RNAi Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Europe Antisense & RNAi Therapeutics Market Size and Forecast By Technology
8.3. Europe Antisense & RNAi Therapeutics Market Size and Forecast By Application
8.4. Europe Antisense & RNAi Therapeutics Market Size and Forecast By Administration
8.5. UK Antisense & RNAi Therapeutics Market
8.5.1. Approval of drug to treat hATTR amyloidosis in the region.
8.6. Germany Antisense & RNAi Therapeutics Market
8.6.1. Biopharmaceuticals companies focusing on R&D of RNA based therapies.
8.7. France Antisense & RNAi Therapeutics Market
8.7.1. Increasing healthcare awareness and emerging need for RNA based therapeutics in the region.
8.8. Rest of Europe Antisense & RNAi Therapeutics Market
9. Asia Pacific Antisense & RNAi Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Asia Pacific Antisense & RNAi Therapeutics Market Size and Forecast By Technology
9.3. Asia Pacific Antisense & RNAi Therapeutics Market Size and Forecast By Technology
9.4. Asia Pacific Antisense & RNAi Therapeutics Market Size and Forecast By Administration
9.5. China Antisense & RNAi Therapeutics Market
9.5.1. Increasing efficacy in synthesizing RNA & DNA molecules.
9.6. India Antisense & RNAi Therapeutics Market
9.6.1. Rising prevalence of cancer emerge need for antisense & RNAi therapeutics.
9.7. Japan Antisense & RNAi Therapeutics Market
9.7.1. Developing therapeutic strategies to regulate miRNA activity
9.8. Rest of Asia Pacific Antisense & RNAi Therapeutics Market
10. Latin America Antisense & RNAi Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Latin America Antisense & RNAi Therapeutics Market Size and Forecast By Technology
10.3. Latin America Antisense & RNAi Therapeutics Market Size and Forecast By Application
10.4. Latin America Antisense & RNAi Therapeutics Market Size and Forecast By Administration
10.4.1. Brazil Antisense & RNAi Therapeutics Market
10.4.1.1. Brazilian Health Regulatory Agency (ANVISA)approved GIVLAARI (givosiran) to treat acute hepatic porphyria (AHP) in adults.
10.4.2. Mexico Antisense & RNAi Therapeutics Market
10.4.2.1. Increasing need for drug development.
10.4.3. Rest of Latin America Antisense & RNAi Therapeutics Market
11. MEA Antisense & RNAi Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. MEA Antisense & RNAi Therapeutics Market Size and Forecast By Technology
11.3. MEA Antisense & RNAi Therapeutics Market Size and Forecast By Application
11.4. MEA Antisense & RNAi Therapeutics Market Size and Forecast By Administration
11.5. South Africa Antisense & RNAi Therapeutics Market
11.5.1.1. Increasing prevalence of cancer in the region.
11.6. Rest of MEA Antisense & RNAi Therapeutics Market
12. Companies in the Antisense & RNAi Therapeutics Market
12.1. Tekmira Pharmaceuticals
12.1.1. Company Snapshot
12.1.2. Company Overview
12.1.3. Financial Performance (2015-2020)
12.1.3.1. Net Revenue
12.1.4. Product Offerings
12.1.5. Recent Initiatives (2017-2020)
12.2. Ionis Pharmaceuticals
12.2.1. Company Snapshot
12.2.2. Company Overview
12.2.3. Financial Performance (2015-2020)
12.2.3.1. Net Revenue
12.2.3.2. Geographical Revenue, 2020
12.2.4. Product Offerings
12.2.5. Recent Initiatives (2017-2020)
12.3. Glaxo Smith Kline
12.3.1. Company Snapshot
12.3.2. Company Overview
12.3.3. Financial Performance (2015-2020)
12.3.3.1. Net Revenue
12.3.3.2. Gross Profit
12.3.3.3. Geographical Revenue, 2020
12.3.4. Product Offerings
12.3.5. Recent Initiatives (2017-2020)
12.4. Alnylam Pharmaceuticals Inc.
12.4.1. Company Snapshot
12.4.2. Company Overview
12.4.3. Financial Performance (2015-2020)
12.4.3.1. Net Revenue
12.4.3.2. Gross Profit
12.4.3.3. Geographical Revenue, 2020
12.4.4. Product Offerings
12.4.5. Recent Initiatives (2017-2020)
12.5. Antisense Therapeutics
12.5.1. Company Snapshot
12.5.2. Company Overview
12.5.3. Financial Performance (2015-2020)
12.5.3.1. Net Revenue
12.5.3.2. Gross Profit
12.5.3.3. Geographical Revenue, 2020
12.5.4. Product Offerings
12.5.5. Recent Initiatives (2017-2020)
12.6. Sanofi-Genzyme
12.6.1. Company Snapshot
12.6.2. Company Overview
12.6.3. Financial Performance (2015-2020)
12.6.3.1. Net Revenue
12.6.3.2. Geographical Revenue, 2020
12.6.4. Product Offerings
12.6.5. Recent Initiatives (2017-2020)
12.7. Silence Therapeutics
12.7.1. Company Snapshot
12.7.2. Company Overview
12.7.3. Financial Performance (2015-2020)
12.7.3.1. Net Revenue
12.7.3.2. Geographical Revenue, 2020
12.7.4. Product Offerings
12.7.5. Recent Initiatives (2017-2020)
12.8. F. Hoffmann-La Roche Ltd
12.8.1. Company Snapshot
12.8.2. Company Overview
12.8.3. Financial Performance (2015-2020)
12.8.3.1. Net Revenue
12.8.3.2. Geographical Revenue, 2020
12.8.4. Product Offerings
12.8.5. Recent Initiatives (2017-2020)
12.9. Sirnaomics, Inc
12.9.1. Company Snapshot
12.9.2. Company Overview
12.9.3. Financial Performance (2015-2020)
12.9.3.1. Net Revenue
12.9.3.2. Geographical Revenue, 2020
12.9.4. Product Offerings
12.9.5. Recent Initiatives (2017-2020)
12.10. Gene Signal
12.10.1. Company Snapshot
12.10.2. Company Overview
12.10.3. Financial Performance (2015-2020)
12.10.3.1. Net Revenue
12.10.3.2. Geographical Revenue, 2020
12.10.4. Product Offerings
12.10.5. Recent Initiatives (2017-2020)
12.11. Other Notable Players
13. Conclusion
14. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Antisense & RNAi Therapeutics Market Drivers & Restraints 2021
Table 7. Antisense & RNAi Therapeutics Submarket Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Antisense & RNAi Therapeutics Submarket Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Antisense & RNAi Therapeutics Submarket Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Antisense & RNAi Therapeutics Submarket Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Antisense & RNAi Therapeutics Submarket Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. RNA Interference Antisense & RNAi Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. RNA Interference Antisense & RNAi Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. RNA Interference Antisense & RNAi Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. RNA Interference Antisense & RNAi Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. RNA Interference Antisense & RNAi Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Antisense RNA Antisense & RNAi Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Antisense RNA Antisense & RNAi Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Antisense RNA Antisense & RNAi Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Antisense RNA Antisense & RNAi Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Antisense RNA Antisense & RNAi Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Antisense & RNAi Therapeutics Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 23. Antisense & RNAi Therapeutics Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Antisense & RNAi Therapeutics Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Antisense & RNAi Therapeutics Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Antisense & RNAi Therapeutics Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Oncology Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Oncology Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Oncology Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Oncology Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Oncology Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Cardiovascular Diseases (CVDs)Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Cardiovascular Diseases (CVDs)Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Cardiovascular Diseases (CVDs)Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Cardiovascular Diseases (CVDs)Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Cardiovascular Diseases (CVDs)Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Infectious Diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Infectious Diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Infectious Diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Infectious Diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Infectious Diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Genetic Disorders Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Genetic Disorders Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Genetic Disorders Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Genetic Disorders Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Genetic Disorders Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Pulmonary Delivery Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Pulmonary Delivery Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Pulmonary Delivery Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Pulmonary Delivery Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Pulmonary Delivery Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Intravenous Injections Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Intravenous Injections Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Intravenous Injections Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Intravenous Injections Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Intravenous Injections Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Intra-dermal Injections Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Intra-dermal Injections Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Intra-dermal Injections Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Intra-dermal Injections Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Intra-dermal Injections Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Regional Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 78. Regional Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Regional Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Regional Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Regional Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 82. North America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 83. North America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 84. North America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 85. North America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 86. North America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 87. North America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 88. North America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 89. North America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 90. North America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 91. North America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 92. North America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 93. North America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031(US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 94. North America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 95. North America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 96. North America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 97. North America Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 98. North America Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 99 North America Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 100. North America Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 101. North America Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 102. US Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 103. US Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 104. US Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 105. US Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 106. US Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Canada Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 108. Canada Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Canada Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Canada Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario W)
Table 111. Canada Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Europe Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 113. Europe Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Europe Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table115. Europe Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Europe Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Europe Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 118. Europe Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Europe Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Europe Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Europe Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Europe Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 123. Europe Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Europe Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Europe Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Europe Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Europe Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 128. Europe Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Europe Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Europe Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Europe Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 132. UK Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133. UK Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134. UK Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 135. UK Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 136. UK Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Germany Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138. Germany Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Germany Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Germany Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Germany Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142. France Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143. France Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144. France Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario U)
Table 145. France Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR % CAGR %), (COVID - Scenario W)
Table 146. France Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Rest of Europe Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148. Rest of Europe Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Rest of Europe Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Rest of Europe Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR%, CAGR %) (COVID - Scenario W)
Table 151. Rest of Europe Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L
Table 167. Asia Pacific Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168. Asia Pacific Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Asia Pacific Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Asia Pacific Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Asia Pacific Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. China Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. China Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. China Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. China Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. China Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177. India Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. India Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. India Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. India Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. India Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. Japan Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183. Japan Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. Japan Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185. Japan Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. Japan Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. RoAPAC Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. RoAPAC Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. RoAPAC Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. RoAPAC Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191. RoAPAC Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. Middle East Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. Middle East Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. Middle East Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195 Middle East Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. Middle East Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. Middle East Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198. Middle East Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. Middle East Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. Middle East Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. Middle East Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202 Middle East Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203 Middle East Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. Middle East Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205. Middle East Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. Middle East Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. Latin America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. Latin America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. Latin America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. Latin America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. Latin America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212. Latin America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213. Latin America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214. Latin America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. Latin America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. Latin America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217. Latin America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 218. Latin America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219 Latin America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220. Latin America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221. Latin America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222 Leading 10 Antisense & RNAi Therapeutics Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 223. Tekmira Pharmaceuticals Profile 2021 (CEO, HQ, Founded, Website)
Table 224. Tekmira Pharmaceuticals Antisense & RNAi Therapeutics Selected Recent Contracts 2021 (Date, Programme Type, Details)
Table 225. Tekmira Pharmaceuticals Antisense & RNAi Therapeutics Product Offering (Segment, Product Offerings)
Table 226. Ionis Pharmaceuticals Profile 2021 (CEO, HQ, Founded, Website)
Table 227. Ionis Pharmaceuticals Antisense & RNAi Therapeutics Product Offering (Segment, Product Offerings)
Table 228. Glaxo Smith Kline Profile 2021 (CEO, HQ, Founded, Website)
Table 229. Glaxo Smith Kline Antisense & RNAi Therapeutics Selected Recent Contracts 2017-2020 (Date, Programme Type, Details)
Table 230. Glaxo Smith Kline Antisense & RNAi Therapeutics Product Offering (Segment, Product Offerings)
Table 231. Alnylam Pharmaceuticals Inc Profile 2021 (CEO, HQ, Founded, Website)
Table 232. Alnylam Pharmaceuticals Inc Selected Recent Contracts 2015-2021 (Date, Programme Type, Details)
Table 233. Alnylam Pharmaceuticals Inc Antisense & RNAi Therapeutics Product Offering (Segment, Product Offerings)
Table 234. Antisense Therapeutics Profile 2021 (CEO, HQ, Founded, Website)
Table 235 Antisense Therapeutics Antisense & RNAi Therapeutics Product Offering (Segment, Product Offerings)
Table 236. Sanofi-Genzyme Profile 2021 (CEO, HQ, Founded, Website)
Table 237. Sanofi-Genzyme Antisense & RNAi Therapeutics Selected Recent Contracts 2015-2021 (Date, Programme Type, Details)
Table 238 Sanofi-Genzyme Antisense & RNAi Therapeutics Product Offering (Segment, Product Offerings)
Table 239. Silence Therapeutics Profile 2021 (CEO, HQ, Founded, Website)
Table 240. Silence Therapeutics Antisense & RNAi Therapeutics Product Offering (Segment, Product Offerings)
Table 241. F. Hoffmann-La Roche Ltd Profile 2021 (CEO, HQ, Founded, Website)
Table 242. F. Hoffmann-La Roche Ltd Antisense & RNAi Therapeutics Product Offering (Segment, Product Offerings)
Table 243. Sirnaomics, Inc Profile 2021 (CEO, HQ, Founded, Website)
Table 244. Sirnaomics Inc Antisense & RNAi Therapeutics Product Offering (Segment, Product Offerings)
Table 245. Gene Signal Profile 2021 (CEO, Total Company Sales US$m, HQ, Founded, No. of Employees, Ticker, Website)
Table 246. Gene Signal Total Company Sales 2015-2021 (US$m, AGR %)
Table 247. Gene Signal Product Offering (Segment, Product Offerings)
Table 248. Other Companies Involved in the Antisense & RNAi Therapeutics Market (Company, Location)
LIST OF FIGURES
Figure 1. Antisense & RNAi Therapeutics Market Type Overview
Figure 2. Antisense & RNAi Therapeutics Market By Technology Overview
Figure 3. Antisense & RNAi Therapeutics Market By Application Overview
Figure 4. Antisense & RNAi Therapeutics Market By Administration Overview
Figure 5 Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 6. Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 7. Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 8. Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 9. Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 10. Antisense & RNAi Therapeutics Submarket Forecast By Technology 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 11. Antisense & RNAi Therapeutics Submarket Forecast By Technology 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 12. Antisense & RNAi Therapeutics Submarket Forecast By Technology 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 13. Antisense & RNAi Therapeutics Submarket Forecast By Technology 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 14. Antisense & RNAi Therapeutics Submarket Forecast By Technology 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 15. Antisense & RNAi Therapeutics Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 16. Antisense & RNAi Therapeutics Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 17. Antisense & RNAi Therapeutics Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 18. Antisense & RNAi Therapeutics Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 19. Antisense & RNAi Therapeutics Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 20. Antisense & RNAi Therapeutics Submarket Forecast By Administration 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 21. Antisense & RNAi Therapeutics Submarket Forecast By Administration 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 22. Antisense & RNAi Therapeutics Submarket Forecast By Administration 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 23. Antisense & RNAi Therapeutics Submarket Forecast By Administration 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 24. Antisense & RNAi Therapeutics Submarket Forecast By Administration 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 25. Regional Antisense & RNAi Therapeutics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (Before COVID)
Figure 26. Regional Antisense & RNAi Therapeutics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure 27. Regional Antisense & RNAi Therapeutics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure 28. Regional Antisense & RNAi Therapeutics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure 29. Regional Antisense & RNAi Therapeutics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure 30. North America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %) (Before COVID)
Figure 31. North America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 32. North America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 33. North America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 34. North America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 35. North America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %) (Before COVID)
Figure 36. North America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 37. North America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 38. North America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 39. North America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 40. North America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %) (Before COVID)
Figure 41. North America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 42. North America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 43. North America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 44. North America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 45. North America Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 46. North America Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 47. North America Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 48. North America Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 49. North America Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 50. US Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 51. US Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 52. US Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 53. US Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 54. US Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 55. Canada Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 56. Canada Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 57. Canada Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 58. Canada Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 59. Canada Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 60. Europe Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M)
Figure 61. Europe Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario V)
Figure 62. Europe Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario U)
Figure 63. Europe Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario W)
Figure 64. Europe Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario L)
Figure 65. Europe Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (Before COVID)
Figure 66. Europe Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 67. Europe Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 68. Europe Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 69. Europe Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 70. Europe Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (Before COVID)
Figure 71. Europe Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario V)
Figure 72. Europe Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario U)
Figure 73. Europe Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario W)
Figure 74. Europe Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario L)
Figure 75. Europe Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 76. Europe Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 77. Europe Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 78. Europe Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 79. Europe Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 80. UK Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 81. UK Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 82. UK Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID – Scenario U)
Figure 83. UK Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 84. UK Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 85. Germany Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 86. Germany Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 87. Germany Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 88. Germany Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 89. Germany Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 90. France Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 91. France Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 92. France Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 93. France Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 94. France Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 95. Rest of Europe Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 96. Rest of Europe Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 97. Rest of Europe Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 98. Rest of Europe Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 99. Rest of Europe Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 100 Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (Before COVID)
Figure 101. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario V)
Figure 102. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario U)
Figure 103. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario W)
Figure 104. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario L)
Figure 105. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M)
Figure 106. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 107. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 108. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 109. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 110. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M)
Figure 111. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario V)
Figure 112. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario U)
Figure 113. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario W)
Figure 114. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario L)
Figure 115. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 116. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 117. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 118. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 119. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 120. China Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 121. China Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 122. China Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 123 China Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 124. China Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 125. India Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 126. India Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 127. India Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 128. India Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 129. India Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 130. Japan Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 131. Japan Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 132. Japan Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 133. Japan Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 134. Japan Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 135. Rest of APAC Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 136. Rest of APAC Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 137 Rest of APAC Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 138. Rest of APAC Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 139. Rest of APAC Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 140. Middle East Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M)
Figure 141. Middle East Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario V)
Figure 142. Middle East Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario U)
Figure 143. Middle East Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario W)
Figure 144. Middle East Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario L)
Figure 145. Middle East Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M)
Figure 146. Middle East Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 147 Middle East Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 148. Middle East Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 149. Middle East Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 150. Middle East Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M)
Figure 151. Middle East Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario V)
Figure 152. Middle East Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario U)
Figure 153. Middle East Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario W)
Figure 154. Middle East Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario L)
Figure 155. Rest of Middle East Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 156. Rest of Middle East Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 157. Rest of Middle East Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 158. Rest of Middle East Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 159. Rest of Middle East Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 160. Latin America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M)
Figure 161. Latin America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario V)
Figure 162. Latin America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario U)
Figure 163. Latin America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario W)
Figure 164. Latin America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario L)
Figure 165. Latin America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M)
Figure 166. Latin America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 167. Latin America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 168. Latin America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 169. Latin America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 170. Latin America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M)
Figure 171. Latin America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario V)
Figure 172. Latin America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario U)
Figure 173. Latin America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario W)
Figure 174. Latin America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario L)
Figure 175. Rest of Latin America Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 176. Rest of Latin America Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 177. Rest of Latin America Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 178. Rest of Latin America Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 179. Rest of Latin America Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 180. Porter’s Five Force Analysis
Companies Mentioned
1. Tekmira Pharmaceuticals
2. Ionis Pharmaceuticals
3. Glaxo Smith Kline
4. Alnylam Pharmaceuticals Inc.
5. Antisense Therapeutics
6. Sanofi-Genzyme
7. Silence Therapeutics
8. F. Hoffmann-La Roche Ltd
9. Sirnaomics Inc.
10. Gene Signal
11. BioNTech
12. Quark Pharmaceuticals,
13. CureVac AG
14. Gradalis Inc.
15. Benitec Biopharma Ltd.
16. Olix Pharmaceuticals
17. Bio-Path Holdings Inc.
18. iCo Therapeutics
19. Synlogic Inc.
20. miRagen Therapeutics Inc.
21. OncoGenex Pharmaceuticals Inc
22. Arrowhead Pharmaceuticals
23. Rexahn Pharmaceutical Inc.
24. Astellas Pharma Inc
25. Bayer AG
26. AstraZeneca
27. Arbutus Biopharma,
28. Moderna Inc.
29. Creative Biolabs
30. Akcea Therapeutics
31. Biomarin/Prosensa
32. Regulus Therapeutics
33. Phio Pharmaceuticals
34. Sarepta Therapeutics
35. Sylentis S.A.
36. Silenseed
37. Dicerna Pharmaceuticals Inc.
38. Eli Lilly and Company
39. Evox Therapeutics Ltd
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered by This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Antisense & RNAi Therapeutics Market
2.1. Antisense & RNAi Therapeutics Market Definition
2.2. By Technology Submarkets Definitions
2.3. By Application Submarkets Definitions
2.4. By Administration Submarkets Definitions
3. Antisense & RNAi Therapeutics Market Overview
3.1. Global Antisense & RNAi Therapeutics Market Size and Forecast by Region
3.2. Global Antisense & RNAi Therapeutics Market Share by Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing collaborations among bio-pharmaceutical companies
3.3.1.2. Increasing pipeline product portfolio
3.3.1.3. Introduction of technological advancements.
3.3.1.4. Government initiatives & funding for R&D.
3.3.2. Market Restraints/Challenges
3.3.2.1. Expensive research programs
3.3.2.2. Delivery of RNAi therapeutics and off-target effects
3.3.3. Opportunities
3.3.3.1. Rising approval &drug launch of RNA therapeutics plays significant role in the growth of the market.
3.3.3.2. Increasing application in molecular diagnostics.
3.3.4. Porter’s Five Forces Analysis
3.3.4.1. Competitive Rivalry
3.3.4.2. Supplier Power
3.3.4.3. Buyer Power
3.3.4.4. Threat of Substitution
3.3.4.5. Threat of New Entry
4. Global Antisense & RNAi Therapeutics Market Analysis and Forecast 2021-2031, By Technology (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. RNA Interference
4.1.2. RNA interference (RNAi) biological response to double-stranded RNA, which intermediates resistance to endogenous parasitic and exogenous pathogenic nucleic acids.
4.1.3. Antisense RNA
4.1.4. Single stranded RNA, which is complementary to a protein coding messenger RNA (mRNA).
5. Global Antisense & RNAi Therapeutics Market Analysis and Forecast, 2021-2031 By Application (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Oncology
5.1.2. Antisense technology, siRNA, and therapeutic mRNA emerge as potential cancer therapeutics.
5.1.3. Cardiovascular Diseases (CVDs)
5.1.4. miRNAs therapeutics have significant potential in evolution of cardiovascular diseases, such as acute myocardial infarction (AMI), fibrosis, and heart failure.
5.1.5. Infectious Diseases
5.1.6. Antisense-based therapeutics have the potential to lead in anti-infective drug development.
5.1.7. Genetic Disorders.
5.1.8. Approval of RNA-targeted drugs for the treatment of rare genetic disease.
5.1.9. Others
6. Global Antisense & RNAi Therapeutics Market Analysis and Forecast, 2021-2031 By Administration (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Pulmonary Delivery
6.1.2. The pulmonary drug delivery have high drug-loading efficiency.
6.1.3. Intravenous Injections
6.1.4. Eliminates drug absorption and breakdown by directly depositing it into the blood.
6.1.5. Intra-dermal Injections
6.1.6. Oligonucleotides short fragments of nucleic acids administered into dermis.
6.1.7. Others
7. North America Antisense & RNAi Therapeutics Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.2. North America Antisense & RNAi Therapeutics Market Size and Forecast By Technology
7.3. North America Antisense & RNAi Therapeutics Market Size and Forecast By Application
7.4. North America Antisense & RNAi Therapeutics Market Size and Forecast By Administration
7.5. U.S. Antisense & RNAi Therapeutics Market
7.5.1. Emerging biopharmaceutical companies to develop RNA based therapeutics.
7.6. Canada Antisense & RNAi Therapeutics Market
7.6.1. Major players involved in developing RNA therapeutics.
8. Europe Antisense & RNAi Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.2. Europe Antisense & RNAi Therapeutics Market Size and Forecast By Technology
8.3. Europe Antisense & RNAi Therapeutics Market Size and Forecast By Application
8.4. Europe Antisense & RNAi Therapeutics Market Size and Forecast By Administration
8.5. UK Antisense & RNAi Therapeutics Market
8.5.1. Approval of drug to treat hATTR amyloidosis in the region.
8.6. Germany Antisense & RNAi Therapeutics Market
8.6.1. Biopharmaceuticals companies focusing on R&D of RNA based therapies.
8.7. France Antisense & RNAi Therapeutics Market
8.7.1. Increasing healthcare awareness and emerging need for RNA based therapeutics in the region.
8.8. Rest of Europe Antisense & RNAi Therapeutics Market
9. Asia Pacific Antisense & RNAi Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.2. Asia Pacific Antisense & RNAi Therapeutics Market Size and Forecast By Technology
9.3. Asia Pacific Antisense & RNAi Therapeutics Market Size and Forecast By Technology
9.4. Asia Pacific Antisense & RNAi Therapeutics Market Size and Forecast By Administration
9.5. China Antisense & RNAi Therapeutics Market
9.5.1. Increasing efficacy in synthesizing RNA & DNA molecules.
9.6. India Antisense & RNAi Therapeutics Market
9.6.1. Rising prevalence of cancer emerge need for antisense & RNAi therapeutics.
9.7. Japan Antisense & RNAi Therapeutics Market
9.7.1. Developing therapeutic strategies to regulate miRNA activity
9.8. Rest of Asia Pacific Antisense & RNAi Therapeutics Market
10. Latin America Antisense & RNAi Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. Latin America Antisense & RNAi Therapeutics Market Size and Forecast By Technology
10.3. Latin America Antisense & RNAi Therapeutics Market Size and Forecast By Application
10.4. Latin America Antisense & RNAi Therapeutics Market Size and Forecast By Administration
10.4.1. Brazil Antisense & RNAi Therapeutics Market
10.4.1.1. Brazilian Health Regulatory Agency (ANVISA)approved GIVLAARI (givosiran) to treat acute hepatic porphyria (AHP) in adults.
10.4.2. Mexico Antisense & RNAi Therapeutics Market
10.4.2.1. Increasing need for drug development.
10.4.3. Rest of Latin America Antisense & RNAi Therapeutics Market
11. MEA Antisense & RNAi Therapeutics Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. MEA Antisense & RNAi Therapeutics Market Size and Forecast By Technology
11.3. MEA Antisense & RNAi Therapeutics Market Size and Forecast By Application
11.4. MEA Antisense & RNAi Therapeutics Market Size and Forecast By Administration
11.5. South Africa Antisense & RNAi Therapeutics Market
11.5.1.1. Increasing prevalence of cancer in the region.
11.6. Rest of MEA Antisense & RNAi Therapeutics Market
12. Companies in the Antisense & RNAi Therapeutics Market
12.1. Tekmira Pharmaceuticals
12.1.1. Company Snapshot
12.1.2. Company Overview
12.1.3. Financial Performance (2015-2020)
12.1.3.1. Net Revenue
12.1.4. Product Offerings
12.1.5. Recent Initiatives (2017-2020)
12.2. Ionis Pharmaceuticals
12.2.1. Company Snapshot
12.2.2. Company Overview
12.2.3. Financial Performance (2015-2020)
12.2.3.1. Net Revenue
12.2.3.2. Geographical Revenue, 2020
12.2.4. Product Offerings
12.2.5. Recent Initiatives (2017-2020)
12.3. Glaxo Smith Kline
12.3.1. Company Snapshot
12.3.2. Company Overview
12.3.3. Financial Performance (2015-2020)
12.3.3.1. Net Revenue
12.3.3.2. Gross Profit
12.3.3.3. Geographical Revenue, 2020
12.3.4. Product Offerings
12.3.5. Recent Initiatives (2017-2020)
12.4. Alnylam Pharmaceuticals Inc.
12.4.1. Company Snapshot
12.4.2. Company Overview
12.4.3. Financial Performance (2015-2020)
12.4.3.1. Net Revenue
12.4.3.2. Gross Profit
12.4.3.3. Geographical Revenue, 2020
12.4.4. Product Offerings
12.4.5. Recent Initiatives (2017-2020)
12.5. Antisense Therapeutics
12.5.1. Company Snapshot
12.5.2. Company Overview
12.5.3. Financial Performance (2015-2020)
12.5.3.1. Net Revenue
12.5.3.2. Gross Profit
12.5.3.3. Geographical Revenue, 2020
12.5.4. Product Offerings
12.5.5. Recent Initiatives (2017-2020)
12.6. Sanofi-Genzyme
12.6.1. Company Snapshot
12.6.2. Company Overview
12.6.3. Financial Performance (2015-2020)
12.6.3.1. Net Revenue
12.6.3.2. Geographical Revenue, 2020
12.6.4. Product Offerings
12.6.5. Recent Initiatives (2017-2020)
12.7. Silence Therapeutics
12.7.1. Company Snapshot
12.7.2. Company Overview
12.7.3. Financial Performance (2015-2020)
12.7.3.1. Net Revenue
12.7.3.2. Geographical Revenue, 2020
12.7.4. Product Offerings
12.7.5. Recent Initiatives (2017-2020)
12.8. F. Hoffmann-La Roche Ltd
12.8.1. Company Snapshot
12.8.2. Company Overview
12.8.3. Financial Performance (2015-2020)
12.8.3.1. Net Revenue
12.8.3.2. Geographical Revenue, 2020
12.8.4. Product Offerings
12.8.5. Recent Initiatives (2017-2020)
12.9. Sirnaomics, Inc
12.9.1. Company Snapshot
12.9.2. Company Overview
12.9.3. Financial Performance (2015-2020)
12.9.3.1. Net Revenue
12.9.3.2. Geographical Revenue, 2020
12.9.4. Product Offerings
12.9.5. Recent Initiatives (2017-2020)
12.10. Gene Signal
12.10.1. Company Snapshot
12.10.2. Company Overview
12.10.3. Financial Performance (2015-2020)
12.10.3.1. Net Revenue
12.10.3.2. Geographical Revenue, 2020
12.10.4. Product Offerings
12.10.5. Recent Initiatives (2017-2020)
12.11. Other Notable Players
13. Conclusion
14. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Antisense & RNAi Therapeutics Market Drivers & Restraints 2021
Table 7. Antisense & RNAi Therapeutics Submarket Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Antisense & RNAi Therapeutics Submarket Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Antisense & RNAi Therapeutics Submarket Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Antisense & RNAi Therapeutics Submarket Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Antisense & RNAi Therapeutics Submarket Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. RNA Interference Antisense & RNAi Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. RNA Interference Antisense & RNAi Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. RNA Interference Antisense & RNAi Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. RNA Interference Antisense & RNAi Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. RNA Interference Antisense & RNAi Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Antisense RNA Antisense & RNAi Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Antisense RNA Antisense & RNAi Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Antisense RNA Antisense & RNAi Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Antisense RNA Antisense & RNAi Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Antisense RNA Antisense & RNAi Therapeutics Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Antisense & RNAi Therapeutics Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 23. Antisense & RNAi Therapeutics Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Antisense & RNAi Therapeutics Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Antisense & RNAi Therapeutics Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Antisense & RNAi Therapeutics Submarket Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Oncology Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Oncology Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Oncology Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Oncology Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Oncology Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Cardiovascular Diseases (CVDs)Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Cardiovascular Diseases (CVDs)Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Cardiovascular Diseases (CVDs)Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Cardiovascular Diseases (CVDs)Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Cardiovascular Diseases (CVDs)Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Infectious Diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Infectious Diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Infectious Diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Infectious Diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Infectious Diseases Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Genetic Disorders Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Genetic Disorders Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Genetic Disorders Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Genetic Disorders Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Genetic Disorders Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Pulmonary Delivery Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Pulmonary Delivery Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Pulmonary Delivery Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Pulmonary Delivery Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Pulmonary Delivery Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Intravenous Injections Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Intravenous Injections Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Intravenous Injections Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Intravenous Injections Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Intravenous Injections Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Intra-dermal Injections Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Intra-dermal Injections Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Intra-dermal Injections Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Intra-dermal Injections Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Intra-dermal Injections Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Others Submarket Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Regional Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 78. Regional Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Regional Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Regional Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Regional Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 82. North America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 83. North America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 84. North America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 85. North America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 86. North America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 87. North America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 88. North America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 89. North America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 90. North America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 91. North America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 92. North America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 93. North America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031(US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 94. North America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 95. North America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 96. North America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 97. North America Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 98. North America Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 99 North America Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 100. North America Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 101. North America Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 102. US Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 103. US Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 104. US Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 105. US Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 106. US Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Canada Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 108. Canada Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Canada Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Canada Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario W)
Table 111. Canada Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Europe Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 113. Europe Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Europe Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table115. Europe Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Europe Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Europe Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 118. Europe Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Europe Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Europe Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Europe Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Europe Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 123. Europe Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Europe Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Europe Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Europe Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Europe Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 128. Europe Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Europe Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Europe Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Europe Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 132. UK Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 133. UK Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 134. UK Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 135. UK Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 136. UK Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Germany Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 138. Germany Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Germany Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Germany Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Germany Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 142. France Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 143. France Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 144. France Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %CAGR %) (COVID - Scenario U)
Table 145. France Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR % CAGR %), (COVID - Scenario W)
Table 146. France Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Rest of Europe Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 148. Rest of Europe Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Rest of Europe Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Rest of Europe Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR%, CAGR %) (COVID - Scenario W)
Table 151. Rest of Europe Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 153. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 157. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. Asia Pacific Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L
Table 167. Asia Pacific Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168. Asia Pacific Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. Asia Pacific Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. Asia Pacific Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. Asia Pacific Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. China Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. China Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. China Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. China Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. China Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177. India Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. India Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. India Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. India Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. India Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. Japan Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183. Japan Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. Japan Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185. Japan Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. Japan Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. RoAPAC Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. RoAPAC Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. RoAPAC Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. RoAPAC Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191. RoAPAC Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. Middle East Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. Middle East Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. Middle East Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195 Middle East Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. Middle East Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. Middle East Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198. Middle East Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. Middle East Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. Middle East Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. Middle East Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202 Middle East Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 203 Middle East Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. Middle East Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205. Middle East Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. Middle East Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. Latin America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. Latin America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. Latin America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. Latin America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. Latin America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212. Latin America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213. Latin America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214. Latin America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. Latin America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. Latin America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217. Latin America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 218. Latin America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219 Latin America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220. Latin America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221. Latin America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222 Leading 10 Antisense & RNAi Therapeutics Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 223. Tekmira Pharmaceuticals Profile 2021 (CEO, HQ, Founded, Website)
Table 224. Tekmira Pharmaceuticals Antisense & RNAi Therapeutics Selected Recent Contracts 2021 (Date, Programme Type, Details)
Table 225. Tekmira Pharmaceuticals Antisense & RNAi Therapeutics Product Offering (Segment, Product Offerings)
Table 226. Ionis Pharmaceuticals Profile 2021 (CEO, HQ, Founded, Website)
Table 227. Ionis Pharmaceuticals Antisense & RNAi Therapeutics Product Offering (Segment, Product Offerings)
Table 228. Glaxo Smith Kline Profile 2021 (CEO, HQ, Founded, Website)
Table 229. Glaxo Smith Kline Antisense & RNAi Therapeutics Selected Recent Contracts 2017-2020 (Date, Programme Type, Details)
Table 230. Glaxo Smith Kline Antisense & RNAi Therapeutics Product Offering (Segment, Product Offerings)
Table 231. Alnylam Pharmaceuticals Inc Profile 2021 (CEO, HQ, Founded, Website)
Table 232. Alnylam Pharmaceuticals Inc Selected Recent Contracts 2015-2021 (Date, Programme Type, Details)
Table 233. Alnylam Pharmaceuticals Inc Antisense & RNAi Therapeutics Product Offering (Segment, Product Offerings)
Table 234. Antisense Therapeutics Profile 2021 (CEO, HQ, Founded, Website)
Table 235 Antisense Therapeutics Antisense & RNAi Therapeutics Product Offering (Segment, Product Offerings)
Table 236. Sanofi-Genzyme Profile 2021 (CEO, HQ, Founded, Website)
Table 237. Sanofi-Genzyme Antisense & RNAi Therapeutics Selected Recent Contracts 2015-2021 (Date, Programme Type, Details)
Table 238 Sanofi-Genzyme Antisense & RNAi Therapeutics Product Offering (Segment, Product Offerings)
Table 239. Silence Therapeutics Profile 2021 (CEO, HQ, Founded, Website)
Table 240. Silence Therapeutics Antisense & RNAi Therapeutics Product Offering (Segment, Product Offerings)
Table 241. F. Hoffmann-La Roche Ltd Profile 2021 (CEO, HQ, Founded, Website)
Table 242. F. Hoffmann-La Roche Ltd Antisense & RNAi Therapeutics Product Offering (Segment, Product Offerings)
Table 243. Sirnaomics, Inc Profile 2021 (CEO, HQ, Founded, Website)
Table 244. Sirnaomics Inc Antisense & RNAi Therapeutics Product Offering (Segment, Product Offerings)
Table 245. Gene Signal Profile 2021 (CEO, Total Company Sales US$m, HQ, Founded, No. of Employees, Ticker, Website)
Table 246. Gene Signal Total Company Sales 2015-2021 (US$m, AGR %)
Table 247. Gene Signal Product Offering (Segment, Product Offerings)
Table 248. Other Companies Involved in the Antisense & RNAi Therapeutics Market (Company, Location)
LIST OF FIGURES
Figure 1. Antisense & RNAi Therapeutics Market Type Overview
Figure 2. Antisense & RNAi Therapeutics Market By Technology Overview
Figure 3. Antisense & RNAi Therapeutics Market By Application Overview
Figure 4. Antisense & RNAi Therapeutics Market By Administration Overview
Figure 5 Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 6. Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 7. Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 8. Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 9. Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 10. Antisense & RNAi Therapeutics Submarket Forecast By Technology 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 11. Antisense & RNAi Therapeutics Submarket Forecast By Technology 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 12. Antisense & RNAi Therapeutics Submarket Forecast By Technology 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 13. Antisense & RNAi Therapeutics Submarket Forecast By Technology 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 14. Antisense & RNAi Therapeutics Submarket Forecast By Technology 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 15. Antisense & RNAi Therapeutics Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 16. Antisense & RNAi Therapeutics Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 17. Antisense & RNAi Therapeutics Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 18. Antisense & RNAi Therapeutics Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 19. Antisense & RNAi Therapeutics Submarket Forecast By Application 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 20. Antisense & RNAi Therapeutics Submarket Forecast By Administration 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 21. Antisense & RNAi Therapeutics Submarket Forecast By Administration 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 22. Antisense & RNAi Therapeutics Submarket Forecast By Administration 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 23. Antisense & RNAi Therapeutics Submarket Forecast By Administration 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 24. Antisense & RNAi Therapeutics Submarket Forecast By Administration 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 25. Regional Antisense & RNAi Therapeutics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (Before COVID)
Figure 26. Regional Antisense & RNAi Therapeutics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario V)
Figure 27. Regional Antisense & RNAi Therapeutics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario U)
Figure 28. Regional Antisense & RNAi Therapeutics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario W)
Figure 29. Regional Antisense & RNAi Therapeutics Market Forecast 2021-2031 (Sales US$M, Global AGR %) (COVID - Scenario L)
Figure 30. North America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %) (Before COVID)
Figure 31. North America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 32. North America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 33. North America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 34. North America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 35. North America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %) (Before COVID)
Figure 36. North America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 37. North America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 38. North America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 39. North America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 40. North America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %) (Before COVID)
Figure 41. North America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 42. North America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 43. North America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 44. North America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 45. North America Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 46. North America Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 47. North America Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 48. North America Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 49. North America Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 50. US Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 51. US Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 52. US Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 53. US Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 54. US Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 55. Canada Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 56. Canada Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 57. Canada Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 58. Canada Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 59. Canada Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 60. Europe Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M)
Figure 61. Europe Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario V)
Figure 62. Europe Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario U)
Figure 63. Europe Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario W)
Figure 64. Europe Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario L)
Figure 65. Europe Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (Before COVID)
Figure 66. Europe Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 67. Europe Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 68. Europe Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 69. Europe Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 70. Europe Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (Before COVID)
Figure 71. Europe Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario V)
Figure 72. Europe Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario U)
Figure 73. Europe Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario W)
Figure 74. Europe Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario L)
Figure 75. Europe Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (Before COVID)
Figure 76. Europe Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 77. Europe Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 78. Europe Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 79. Europe Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 80. UK Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 81. UK Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 82. UK Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID – Scenario U)
Figure 83. UK Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 84. UK Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 85. Germany Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 86. Germany Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 87. Germany Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 88. Germany Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 89. Germany Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 90. France Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 91. France Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 92. France Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 93. France Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 94. France Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 95. Rest of Europe Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 96. Rest of Europe Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 97. Rest of Europe Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 98. Rest of Europe Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 99. Rest of Europe Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 100 Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (Before COVID)
Figure 101. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario V)
Figure 102. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario U)
Figure 103. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario W)
Figure 104. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario L)
Figure 105. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M)
Figure 106. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 107. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 108. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 109. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 110. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M)
Figure 111. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario V)
Figure 112. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario U)
Figure 113. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario W)
Figure 114. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario L)
Figure 115. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, AGR %) (Before COVID)
Figure 116. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario V)
Figure 117. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario U)
Figure 118. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario W)
Figure 119. Asia-Pacific Antisense & RNAi Therapeutics Market Forecast by Country 2021-2031 (US$M, Global AGR %) (COVID - Scenario L)
Figure 120. China Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 121. China Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 122. China Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 123 China Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 124. China Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 125. India Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 126. India Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 127. India Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 128. India Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 129. India Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 130. Japan Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 131. Japan Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 132. Japan Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 133. Japan Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 134. Japan Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 135. Rest of APAC Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (Before COVID)
Figure 136. Rest of APAC Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 137 Rest of APAC Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 138. Rest of APAC Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 139. Rest of APAC Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 140. Middle East Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M)
Figure 141. Middle East Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario V)
Figure 142. Middle East Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario U)
Figure 143. Middle East Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario W)
Figure 144. Middle East Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario L)
Figure 145. Middle East Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M)
Figure 146. Middle East Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 147 Middle East Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 148. Middle East Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 149. Middle East Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 150. Middle East Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M)
Figure 151. Middle East Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario V)
Figure 152. Middle East Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario U)
Figure 153. Middle East Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario W)
Figure 154. Middle East Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario L)
Figure 155. Rest of Middle East Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 156. Rest of Middle East Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 157. Rest of Middle East Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 158. Rest of Middle East Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 159. Rest of Middle East Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 160. Latin America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M)
Figure 161. Latin America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario V)
Figure 162. Latin America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario U)
Figure 163. Latin America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario W)
Figure 164. Latin America Antisense & RNAi Therapeutics Market Forecast By Technology 2021-2031 (US$M) (COVID - Scenario L)
Figure 165. Latin America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M)
Figure 166. Latin America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario V)
Figure 167. Latin America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario U)
Figure 168. Latin America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario W)
Figure 169. Latin America Antisense & RNAi Therapeutics Market Forecast By Application 2021-2031 (US$M) (COVID - Scenario L)
Figure 170. Latin America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M)
Figure 171. Latin America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario V)
Figure 172. Latin America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario U)
Figure 173. Latin America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario W)
Figure 174. Latin America Antisense & RNAi Therapeutics Market Forecast By Administration 2021-2031 (US$M) (COVID - Scenario L)
Figure 175. Rest of Latin America Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %)
Figure 176. Rest of Latin America Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario V)
Figure 177. Rest of Latin America Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario U)
Figure 178. Rest of Latin America Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario W)
Figure 179. Rest of Latin America Antisense & RNAi Therapeutics Market Forecast 2021-2031 (US$M, AGR %) (COVID - Scenario L)
Figure 180. Porter’s Five Force Analysis
Companies Mentioned
1. Tekmira Pharmaceuticals
2. Ionis Pharmaceuticals
3. Glaxo Smith Kline
4. Alnylam Pharmaceuticals Inc.
5. Antisense Therapeutics
6. Sanofi-Genzyme
7. Silence Therapeutics
8. F. Hoffmann-La Roche Ltd
9. Sirnaomics Inc.
10. Gene Signal
11. BioNTech
12. Quark Pharmaceuticals,
13. CureVac AG
14. Gradalis Inc.
15. Benitec Biopharma Ltd.
16. Olix Pharmaceuticals
17. Bio-Path Holdings Inc.
18. iCo Therapeutics
19. Synlogic Inc.
20. miRagen Therapeutics Inc.
21. OncoGenex Pharmaceuticals Inc
22. Arrowhead Pharmaceuticals
23. Rexahn Pharmaceutical Inc.
24. Astellas Pharma Inc
25. Bayer AG
26. AstraZeneca
27. Arbutus Biopharma,
28. Moderna Inc.
29. Creative Biolabs
30. Akcea Therapeutics
31. Biomarin/Prosensa
32. Regulus Therapeutics
33. Phio Pharmaceuticals
34. Sarepta Therapeutics
35. Sylentis S.A.
36. Silenseed
37. Dicerna Pharmaceuticals Inc.
38. Eli Lilly and Company
39. Evox Therapeutics Ltd
Companies Profiled in the Report
1. Tekmira Pharmaceuticals
2. Ionis Pharmaceuticals
3. Glaxo Smith Kline
4. Alnylam Pharmaceuticals Inc.
5. Antisense Therapeutics
6. Sanofi-Genzyme
7. Silence Therapeutics
8. F. Hoffmann-La Roche Ltd
9. Sirnaomics Inc.
10. Gene Signal
11. BioNTech
12. Quark Pharmaceuticals,
13. CureVac AG
14. Gradalis Inc.
List of Companies Mentioned in the Report:
1. Tekmira Pharmaceuticals
2. Ionis Pharmaceuticals
3. Glaxo Smith Kline
4. Alnylam Pharmaceuticals Inc.
5. Antisense Therapeutics
6. Sanofi-Genzyme
7. Silence Therapeutics
8. F. Hoffmann-La Roche Ltd
9. Sirnaomics Inc.
10. Gene Signal
11. BioNTech
12. Quark Pharmaceuticals,
13. CureVac AG
14. Gradalis Inc.
15. Benitec Biopharma Ltd.
16. Olix Pharmaceuticals
17. Bio-Path Holdings Inc.
18. iCo Therapeutics
19. Synlogic Inc.
20. miRagen Therapeutics Inc.
21. OncoGenex Pharmaceuticals Inc
22. Arrowhead Pharmaceuticals
23. Rexahn Pharmaceutical Inc.
24. Astellas Pharma Inc
25. Bayer AG
26. AstraZenca
27. Arbutus Biopharma,
28. Moderna Inc.
29. Creative Biolabs
30. Akcea Therapeutics
31. Biomarin/Prosensa
32. Regulus Therapeutics
33. Phio Pharmaceuticals
34. Sarepta Therapeutics
35. Sylentis S.A.
36. Silenseed
37. Dicerna Pharmaceuticals Inc.
38. Eli Lilly and Company
39. Evox Therapeutics Ltd
List of Organizations Mentioned in the Report
1. National Center for Biotechnology Information,
2. Department of Health
3. American College of Clinical Pharmacology
4. National Association for Biomedical Research
5. National Institutes of Health
6. Organic Process Research & Development
7. The European Medicines Agency (EMA)
8. The Global Health Security Agenda (GHSA)
9. U.S. Center for Disease Control and Prevention (CDC)
10. U.S. Department of Health & Human Services
11. US Food & Drug Administration
12. US National Library of Medicine
13. World Health Organization
14. National Institute of Allergy and Infectious Diseases (NIAID)
15. Biomedical Advanced Research and Development Authority (BARDA).
16. American Journal of Infection Control (AJIC)
17. Infection Control & Hospital Epidemiology
18. U.S. Environmental Protection Agency
19. American College of Cardiology
20. American Heart Association
21. Center for Disease Control and Prevention CDC
22. Center for Diseases Dynamics, Economics & Policy (CDDEP)
1. Tekmira Pharmaceuticals
2. Ionis Pharmaceuticals
3. Glaxo Smith Kline
4. Alnylam Pharmaceuticals Inc.
5. Antisense Therapeutics
6. Sanofi-Genzyme
7. Silence Therapeutics
8. F. Hoffmann-La Roche Ltd
9. Sirnaomics Inc.
10. Gene Signal
11. BioNTech
12. Quark Pharmaceuticals,
13. CureVac AG
14. Gradalis Inc.
List of Companies Mentioned in the Report:
1. Tekmira Pharmaceuticals
2. Ionis Pharmaceuticals
3. Glaxo Smith Kline
4. Alnylam Pharmaceuticals Inc.
5. Antisense Therapeutics
6. Sanofi-Genzyme
7. Silence Therapeutics
8. F. Hoffmann-La Roche Ltd
9. Sirnaomics Inc.
10. Gene Signal
11. BioNTech
12. Quark Pharmaceuticals,
13. CureVac AG
14. Gradalis Inc.
15. Benitec Biopharma Ltd.
16. Olix Pharmaceuticals
17. Bio-Path Holdings Inc.
18. iCo Therapeutics
19. Synlogic Inc.
20. miRagen Therapeutics Inc.
21. OncoGenex Pharmaceuticals Inc
22. Arrowhead Pharmaceuticals
23. Rexahn Pharmaceutical Inc.
24. Astellas Pharma Inc
25. Bayer AG
26. AstraZenca
27. Arbutus Biopharma,
28. Moderna Inc.
29. Creative Biolabs
30. Akcea Therapeutics
31. Biomarin/Prosensa
32. Regulus Therapeutics
33. Phio Pharmaceuticals
34. Sarepta Therapeutics
35. Sylentis S.A.
36. Silenseed
37. Dicerna Pharmaceuticals Inc.
38. Eli Lilly and Company
39. Evox Therapeutics Ltd
List of Organizations Mentioned in the Report
1. National Center for Biotechnology Information,
2. Department of Health
3. American College of Clinical Pharmacology
4. National Association for Biomedical Research
5. National Institutes of Health
6. Organic Process Research & Development
7. The European Medicines Agency (EMA)
8. The Global Health Security Agenda (GHSA)
9. U.S. Center for Disease Control and Prevention (CDC)
10. U.S. Department of Health & Human Services
11. US Food & Drug Administration
12. US National Library of Medicine
13. World Health Organization
14. National Institute of Allergy and Infectious Diseases (NIAID)
15. Biomedical Advanced Research and Development Authority (BARDA).
16. American Journal of Infection Control (AJIC)
17. Infection Control & Hospital Epidemiology
18. U.S. Environmental Protection Agency
19. American College of Cardiology
20. American Heart Association
21. Center for Disease Control and Prevention CDC
22. Center for Diseases Dynamics, Economics & Policy (CDDEP)
Download sample pages
Complete the form below to download your free sample pages for Antisense and RNAi Therapeutics Market Report to 2031Related reports
-
NGS-Based RNA Sequencing Market Report 2021-2031
The market is expected to be driven by key factors such as rising cancer prevalence, government funding support in genetic...Full DetailsPublished: 05 May 2021 -
Next-Generation Sequencing Market Report 2020-2030
With the reducing cost of sequencing, Next Generation Sequencing (NGS) is expected to witness diversification into a large number of...
Full DetailsPublished: 01 January 1970 -
RNA Analysis/Transcriptomics Market Report 2020-2030
Rising preference for personalised medicine in developed as well developing economies coupled with increasing investment by biotechnological and pharmaceutical companies...
Full DetailsPublished: 15 March 2021 -
mRNA Vaccines Market Report 2021-2031
The development of mRNA vaccines is driven by new biotechnologies and nanotechnologies. Emerging delivery technologies, such as electroporation (EP), innovative...Full DetailsPublished: 01 October 2020 -
Biobanking Market Report 2021-2031
In clinical trials relating to COVID-19, COVID-19 biobanks will play an important role. These biobanks will play an instrumental role...Full DetailsPublished: 21 October 2020
Download sample pages
Complete the form below to download your free sample pages for Antisense and RNAi Therapeutics Market Report to 2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: jamie.roberts@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Jamie Roberts stating your chosen report title to jamie.roberts@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email jamie.roberts@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034
The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.
18 April 2024
Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034
The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.
17 April 2024
Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034
The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.
12 April 2024
Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034
The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.
11 April 2024
